DK Business Network
The Good Bug, a rising player in India’s wellness space, has raised ₹100 crore in Series B funding. The round was led by Susquehanna Asia Venture Capital, with participation from Fireside Ventures.
Founded in 2022 by Keshav Biyani and Prabhu Karthikeyan, the startup offers science-backed probiotic and gut health products targeting digestion, immunity, and metabolism. The funds will support expanded R&D, clinical trials, and nationwide distribution.
Riding a wave of demand for microbiome-based solutions, The Good Bug has already surpassed ₹100 crore in revenue in under three years. Its new offering, the Advanced Metabolic System, is positioned as a natural, side-effect-free alternative to popular GLP-1 weight-loss drugs.
Susquehanna Asia’s backing reflects growing VC interest in evidence-driven wellness startups in India. The Good Bug’s quick commercial success and focus on therapeutic-grade efficacy set it apart in a crowded health-tech ecosystem.
As health-conscious consumers look beyond fads for real, research-backed impact, The Good Bug is carving out a leadership role. With a blend of clinical ambition and consumer accessibility, it’s not just scaling—it’s shaping a category.
Instagram: Click here
LinkedIn: Click here
For Collaboration and Business: dkbusinessnetwork@gmail.com
